Gaudium IVF & Women Health Quarterly Results for Trading Insights
In Mar 2026, Gaudium IVF & Women Health (GAUDIUMIVF) reported revenue ₹31 Cr and net profit ₹8 Cr — revenue +14.8% YoY. Browse GAUDIUMIVF financial statements for revenue, profit, balance sheet and cash flow data.
GAUDIUMIVF Quarterly Results — Revenue, Profit & EPS Highlights
Gaudium IVF & Women Health latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Gaudium IVF & Women Health share price today.
- Revenue of ₹31 Cr in Mar 2026 (+47.6% vs Jun 2026, +14.8% vs Mar 2025)
- Net Profit of ₹8 Cr in Mar 2026 (+300.0% vs Jun 2026, +14.3% vs Mar 2025)
- EBITDA of ₹12 Cr in Mar 2026 (+200.0% vs Jun 2026)
- Operating Margin of 40.0% in Mar 2026 (+27.0pp vs Jun 2026)
- Earnings Per Share of ₹1.34 in Mar 2026 (+436.0% vs Jun 2026)
Gaudium IVF & Women Health Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GAUDIUMIVF quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 31 | 21 | 32 | 27 | 18 | 47.6% | 14.8% |
| Net Profit (₹ Cr) | 8 | 2 | 9 | 7 | 3 | - | - |
| EBITDA (₹ Cr) | 12 | 4 | 14 | 9 | 5 | - | - |
| EPS (₹) | 1.34 | 0.25 | 1.53 | 1.05 | 0.50 | - | - |
| Operating Margin (%) | 40.0% | 13.0% | 43.0% | 32.0% | 29.0% | - | - |
GAUDIUMIVF Share Price Trend — 1-Year Movement Across Quarterly Results
Gaudium IVF & Women Health 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore GAUDIUMIVF price movement history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GAUDIUMIVF vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gaudium IVF & Women Health latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1900.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.1 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8560.0 | 2,986 | 751 | -5.0% | - | 25.2% | 302.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5013.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 435.5 |
|
Cipla
Mar 2026 |
₹114,875.60 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1104.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 87.3 |
All amounts in ₹ Crores